Award
National Heart, Lung, and Blood Institute 1R44HL182590-01
IntelliStent: A minimally Invasive, Adjustable Pulmonary Flow Restrictor System for Congenital and Acquired Heart Disease
Recipient
HEARTPOINT GLOBAL INC
Award Amount
$1,771,084.00
Ceiling
$1,771,084.00
Awarded
August 22, 2025
Identifier
1R44HL182590-01
Award for developing a minimally invasive, adjustable pulmonary flow restrictor system for congenital and acquired heart disease, focusing on neonatal and infant patients, including preclinical and biocompatibility testing and manufacturing optimization.
Description
The project aims to develop a downsized, biocompatible, and manufacturable version of the IntelliStent device suitable for neonatal and infant patients. The project includes preclinical testing, biocompatibility testing, and manufacturing process optimization. The project emphasizes innovative minimally invasive treatment options for pediatric congenital and acquired heart disease.